Clinical Review

In the treatment of select patients with rheumatoid arthritis (RA), otilimab is neither better than placebo nor noninferior to sarilumab in terms of the proportion of patients achieving an American College of Rheumatology ≥20 percent response (ACR20), according to the results of the phase III ContRAst 3 study.

Use of a chemometric approach appears helpful in the evaluation of interactions between antiretroviral medications and food, suggests a recent study.

Treatment outcomes with nucleos(t)ide analogues for hepatitis B patients appear to differ by sex, such that men are more likely to have biochemical response and achieve clinical remission than women, a study has shown.

Treatment with dupilumab appears to be safe and effective in the treatment of patients with bullous pemphigoid (BP), yielding significant improvements in symptoms with a favourable safety profile, according to a study.

For patients who undergo adalimumab tapering after achieving remission, factors such as age, race, and duration of disease remission on adalimumab appear to impact the risk of relapse, according to a study.

Treatment with tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for type 2 diabetes, leads to substantial reductions in weight despite an increase in gastrointestinal symptoms, according to the results of a meta-analysis.

In the treatment of patients with 3-vessel coronary artery disease (CAD), fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) does not differ from coronary artery bypass grafting (CABG) in terms of the incidence of the composite of death, myocardial infarction (MI), or stroke, according to 3-year data from the FAME 3* trial.

For patients with hepatocellular carcinoma (HCC), the use of antidepressants after diagnosis may signal increased overall and cancer-specific survival, according to a study.

Treatment with zuranolone 50 mg/day in adults with major depressive disorder (MDD) results in greater improvements in depressive symptoms at day 15, demonstrating a rapid time to effect (day 3), and is generally well tolerated, with no new safety concerns compared with lower dosages, reports a study.

Local intranasal treatment with budesonide does not appear to be effective for persistent hyposmia in patients with nonsevere COVID-19, according to a study.